CIBC Asset Management
KRYS icon

CIBC Asset Management’s Krystal Biotech KRYS Stock Holding History

CIBC Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$229K Hold
888
– – ﹤0.01% 1151
2025
Q4 		$219K Buy
+888
New +$187K ﹤0.01% 1160
2024
Q4 		– Sell
-1,378
Closed -$251K – 1265
2024
Q3 		$251K Buy
1,378
+15
+1% +$2.89K ﹤0.01% 963
2024
Q2 		$250K Buy
+1,363
New +$229K ﹤0.01% 895

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIBC Asset Management's KRYS Position: Q1 2026 in Review

CIBC Asset Management held its Krystal Biotech (KRYS) position steady in Q1 2026 at 888 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #1151.

CIBC Asset Management first reported a position in KRYS in Q2 2024 and has held it in 4 quarters since. The position peaked at $251K in Q3 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • CIBC Asset Management held 888 shares of Krystal Biotech worth $229K as of Q1 2026.
  • CIBC Asset Management left its Krystal Biotech share count unchanged in Q1 2026.
  • Krystal Biotech made up ﹤0.01% of CIBC Asset Management's portfolio in Q1 2026, its #1151 holding.
  • CIBC Asset Management first reported a position in Krystal Biotech in Q2 2024 and has held it in 4 quarters since.
  • CIBC Asset Management's Krystal Biotech position peaked at $251K in Q3 2024.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on CIBC Asset Management's 13F filing for Q1 2026, filed 12 May 2026.